Zylox-Tonbridge Medical Technology Co., Ltd. Fundamental Analysis
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamental Analysis
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK) shows moderate financial fundamentals with a PE ratio of 22.22, profit margin of 22.91%, and ROE of 7.59%. The company generates $1.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 67.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2190.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2190.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent2190.HK trades at attractive valuation levels.
Growth Score
Moderate2190.HK shows steady but slowing expansion.
Financial Health Score
Excellent2190.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate2190.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2190.HK Expensive or Cheap?
P/E Ratio
2190.HK trades at 22.22 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 2190.HK's PEG of 0.18 indicates potential undervaluation.
Price to Book
The market values Zylox-Tonbridge Medical Technology Co., Ltd. at 1.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 24.85 times EBITDA. This signals the market has high growth expectations.
How Well Does 2190.HK Make Money?
Net Profit Margin
For every $100 in sales, Zylox-Tonbridge Medical Technology Co., Ltd. keeps $22.91 as profit after all expenses.
Operating Margin
Core operations generate 18.59 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $7.59 in profit for every $100 of shareholder equity.
ROA
Zylox-Tonbridge Medical Technology Co., Ltd. generates $6.78 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Zylox-Tonbridge Medical Technology Co., Ltd. generates strong operating cash flow of $386.52M, reflecting robust business health.
Free Cash Flow
Zylox-Tonbridge Medical Technology Co., Ltd. generates strong free cash flow of $274.69M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.88 in free cash annually.
FCF Yield
2190.HK converts 5.39% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
22.22
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.18
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.96
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.98
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.08
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.06
vs 25 benchmark
How 2190.HK Stacks Against Its Sector Peers
| Metric | 2190.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 22.22 | 29.60 | Better (Cheaper) |
| ROE | 7.59% | 418.00% | Weak |
| Net Margin | 22.91% | -11442.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.78 | Strong (Low Leverage) |
| Current Ratio | 5.98 | 5.13 | Strong Liquidity |
| ROA | 6.78% | -74.00% (disorted) | Weak |
2190.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Zylox-Tonbridge Medical Technology Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation